{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:42:42Z","timestamp":1740163362225,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s13555-023-01023-w","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T17:01:43Z","timestamp":1694710903000},"page":"2609-2620","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The IMPACT of the COVID-19 Pandemic on Prescription Drug Use in Patients with Psoriasis Vulgaris in Germany"],"prefix":"10.1007","volume":"13","author":[{"given":"Maria","family":"Kahn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffeni","family":"Papukchieva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Jacyshyn-Owen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Eberl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2575-467X","authenticated-orcid":false,"given":"Sebastian","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Otten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2198-9925","authenticated-orcid":false,"given":"Benjamin","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"key":"1023_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13858","volume":"33","author":"\u00d6F Elmas","year":"2020","unstructured":"Elmas \u00d6F, Demirba\u015f A, Kutlu \u00d6, Ba\u011fc\u0131er F, Metin MS, \u00d6zyurt K, et\u00a0al. Psoriasis and COVID-19: a narrative review with treatment considerations. Dermatol Ther. 2020;33: e13858. https:\/\/doi.org\/10.1111\/dth.13858.","journal-title":"Dermatol Ther"},{"key":"1023_CR2","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1111\/ene.14555","volume":"28","author":"G Bsteh","year":"2021","unstructured":"Bsteh G, Bitschnau C, Hegen H, Auer M, Di Pauli F, Rommer P, et\u00a0al. Multiple sclerosis and COVID-19: How many are at risk? Eur J Neurol. 2021;28:3369\u201374. https:\/\/doi.org\/10.1111\/ene.14555.","journal-title":"Eur J Neurol"},{"key":"1023_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/all.14657","volume":"76","author":"Y-D Gao","year":"2021","unstructured":"Gao Y-D, Ding M, Dong X, Zhang J-J, Kursat Azkur A, Azkur D, et\u00a0al. Risk factors for severe and critically ill COVID-19 patients: a review. Allergy. 2021;76:428\u201355. https:\/\/doi.org\/10.1111\/all.14657.","journal-title":"Allergy"},{"key":"1023_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fcimb.2019.00007","volume":"9","author":"MJE Visser","year":"2019","unstructured":"Visser MJE, Kell DB, Pretorius E. Bacterial dysbiosis and translocation in psoriasis vulgaris. Front Cell Infect Microbiol. 2019;9:7. https:\/\/doi.org\/10.3389\/fcimb.2019.00007.","journal-title":"Front Cell Infect Microbiol"},{"key":"1023_CR5","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397:1301\u201315. https:\/\/doi.org\/10.1016\/S0140-6736(20)32549-6.","journal-title":"Lancet"},{"key":"1023_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590","volume":"369","author":"R Parisi","year":"2020","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM, et\u00a0al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369: m1590. https:\/\/doi.org\/10.1136\/bmj.m1590.","journal-title":"BMJ"},{"unstructured":"Augustin M, Glaeske G, Hagenstr\u00f6m K. Psoriasis Report - Ergebnisse von Routinedaten-Analysen der Techniker Krankenkasse aus den Jahren 2017\u20132019  n.d. https:\/\/www.tk.de\/resource\/blob\/2105142\/fcbbc585441b5652a0e64d7daeaa464b\/hautreport-psoriasis-lang-data.pdf","key":"1023_CR7"},{"key":"1023_CR8","doi-asserted-by":"publisher","first-page":"E7488","DOI":"10.3390\/ijms21207488","volume":"21","author":"M Tokuyama","year":"2020","unstructured":"Tokuyama M, Mabuchi T. New treatment addressing the pathogenesis of psoriasis. Int J Mol Sci. 2020;21:E7488. https:\/\/doi.org\/10.3390\/ijms21207488.","journal-title":"Int J Mol Sci"},{"key":"1023_CR9","doi-asserted-by":"publisher","first-page":"E1475","DOI":"10.3390\/ijms20061475","volume":"20","author":"A Rendon","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20:E1475. https:\/\/doi.org\/10.3390\/ijms20061475.","journal-title":"Int J Mol Sci"},{"unstructured":"Augustin M, Kiedrowski von R, K\u00f6rber A, Mrowietz U, Reich K, Thaci D. Verfahrensweise bei der Systemtherapie von Patienten mit Psoriasis w\u00e4hrend der pandemischen Phase von SARS-CoV-2 (Coronavirus) 2020. https:\/\/www.psobest.de\/wp-content\/uploads\/2020\/03\/RundschreibenPsoBestPsoNetCoronafinal1.0.pdf","key":"1023_CR10"},{"key":"1023_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00377-9","author":"ND Brownstone","year":"2020","unstructured":"Brownstone ND, Thibodeaux QG, Reddy VD, Myers BA, Chan SY, Bhutani T, et\u00a0al. Novel Coronavirus Disease (COVID-19) and biologic therapy in psoriasis: infection risk and patient counseling in uncertain times. Dermatol Ther (Heidelb). 2020. https:\/\/doi.org\/10.1007\/s13555-020-00377-9.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1023_CR12","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/ced.14105","volume":"45","author":"H Yang","year":"2020","unstructured":"Yang H, Zheng J. Influence of stress on the development of psoriasis. Clin Exp Dermatol. 2020;45:284\u20138. https:\/\/doi.org\/10.1111\/ced.14105.","journal-title":"Clin Exp Dermatol"},{"key":"1023_CR13","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/ijd.14032","volume":"57","author":"L Rousset","year":"2018","unstructured":"Rousset L, Halioua B. Stress and psoriasis. Int J Dermatol. 2018;57:1165\u201372. https:\/\/doi.org\/10.1111\/ijd.14032.","journal-title":"Int J Dermatol"},{"key":"1023_CR14","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2174\/1570159X19666210311103136","volume":"19","author":"S Salim","year":"2021","unstructured":"Salim S. The stress of the COVID-19 pandemic: beyond the data. Curr Neuropharmacol. 2021;19:1161\u20133. https:\/\/doi.org\/10.2174\/1570159X19666210311103136.","journal-title":"Curr Neuropharmacol"},{"key":"1023_CR15","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00737-020-01092-2","volume":"23","author":"M Almeida","year":"2020","unstructured":"Almeida M, Shrestha AD, Stojanac D, Miller LJ. The impact of the COVID-19 pandemic on women\u2019s mental health. Arch Womens Ment Health. 2020;23:741\u20138. https:\/\/doi.org\/10.1007\/s00737-020-01092-2.","journal-title":"Arch Womens Ment Health"},{"key":"1023_CR16","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1111\/ddg.14508_g","volume":"19","author":"A Nast","year":"2021","unstructured":"Nast A, Altenburg A, Augustin M, Boehncke W-H, H\u00e4rle P, Klaus J, et\u00a0al. Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm - Teil 1: Therapieziele und Therapieempfehlungen. J Dtsch Dermatol Ges. 2021;19:934\u201351. https:\/\/doi.org\/10.1111\/ddg.14508_g.","journal-title":"J Dtsch Dermatol Ges"},{"unstructured":"Bundesl\u00e4nder | RKI COVID-19 Germany n.d. https:\/\/experience.arcgis.com\/experience\/478220a4c454480e823b17327b2bf1d4\/page\/Bundesl%C3%A4nder\/ (accessed Aug 22, 2022).","key":"1023_CR17"},{"unstructured":"Schleswig-Holstein - Zahlen zur Bev\u00f6lkerung. schleswig-holstein.de n.d. https:\/\/www.schleswig-holstein.de\/DE\/landesportal\/land-und-leute\/zahlen-fakten\/bevoelkerung\/bevoelkerung_node.html (accessed Aug 22, 2022).","key":"1023_CR18"},{"unstructured":"Sachsen SL des F. Bev\u00f6lkerungsstand - Statistik - Statistik - sachsen.de n.d. https:\/\/www.statistik.sachsen.de\/html\/bevoelkerungsstand-einwohner.html (accessed Aug 22, 2022).","key":"1023_CR19"},{"key":"1023_CR20","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.jaad.2015.02.1099","volume":"72","author":"J Vanderpuye-Orgle","year":"2015","unstructured":"Vanderpuye-Orgle J, Zhao Y, Lu J, Shrestha A, Sexton A, Seabury S, et\u00a0al. Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol. 2015;72:961\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2015.02.1099. (e5).","journal-title":"J Am Acad Dermatol"},{"key":"1023_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1684\/ejd.2021.4016","volume":"31","author":"N Ninosu","year":"2021","unstructured":"Ninosu N, Roehrich F, Diehl K, Peitsch WK, Schaarschmidt M-L. Psoriasis care during the time of COVID-19: real-world data on changes in treatments and appointments from a German university hospital. Eur J Dermatol. 2021;31:183\u201391. https:\/\/doi.org\/10.1684\/ejd.2021.4016.","journal-title":"Eur J Dermatol"},{"unstructured":"Psoriasis drives autoimmune sales growth n.d. https:\/\/www.iqvia.com\/blogs\/2019\/03\/psoriasis-drives-autoimmune-sales-growth (accessed Aug 23, 2022).","key":"1023_CR22"},{"unstructured":"Psoriasis Drugs MArket Research Report n.d. https:\/\/www.psmarketresearch.com\/market-analysis\/psoriasis-drugs-market-outlook.","key":"1023_CR23"},{"unstructured":"Corona-Krise: Lieferengpass bei Medikamenten n.d. https:\/\/www.ndr.de\/ratgeber\/gesundheit\/Corona-Krise-Lieferengpass-bei-Medikamenten,coronavirus1532.html.","key":"1023_CR24"},{"key":"1023_CR25","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1016\/j.jid.2018.01.039","volume":"138","author":"J Takeshita","year":"2018","unstructured":"Takeshita J, Shin DB, Ogdie A, Gelfand JM. Risk of serious infection, opportunistic infection, and herpes zoster among patients with Psoriasis in the United Kingdom. J Invest Dermatol. 2018;138:1726\u201335. https:\/\/doi.org\/10.1016\/j.jid.2018.01.039.","journal-title":"J Invest Dermatol"},{"key":"1023_CR26","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1001\/jamadermatol.2013.5015","volume":"149","author":"H Yeung","year":"2013","unstructured":"Yeung H, Takeshita J, Mehta NN, Kimmel SE, Ogdie A, Margolis DJ, et\u00a0al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 2013;149:1173\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2013.5015.","journal-title":"JAMA Dermatol"},{"key":"1023_CR27","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1038\/jid.2009.112","volume":"129","author":"JM Gelfand","year":"2009","unstructured":"Gelfand JM, Dommasch ED, Shin DB, Azfar RS, Kurd SK, Wang X, et\u00a0al. The risk of stroke in patients with psoriasis. J Invest Dermatol. 2009;129:2411\u20138. https:\/\/doi.org\/10.1038\/jid.2009.112.","journal-title":"J Invest Dermatol"},{"key":"1023_CR28","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1093\/eurheartj\/ehx145","volume":"39","author":"A Ogdie","year":"2018","unstructured":"Ogdie A, Kay McGill N, Shin DB, Takeshita J, Jon Love T, Noe MH, et\u00a0al. Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study. Eur Heart J. 2018;39:3608\u201314. https:\/\/doi.org\/10.1093\/eurheartj\/ehx145.","journal-title":"Eur Heart J"},{"key":"1023_CR29","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1161\/ATVBAHA.119.314008","volume":"40","author":"MS Garshick","year":"2020","unstructured":"Garshick MS, Tawil M, Barrett TJ, Salud-Gnilo CM, Eppler M, Lee A, et\u00a0al. Activated platelets induce endothelial cell inflammatory response in psoriasis via COX-1. Arterioscler Thromb Vasc Biol. 2020;40:1340\u201351. https:\/\/doi.org\/10.1161\/ATVBAHA.119.314008.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1023_CR30","doi-asserted-by":"publisher","first-page":"E728","DOI":"10.3390\/vaccines8040728","volume":"8","author":"P Gisondi","year":"2020","unstructured":"Gisondi P, Bellinato F, Chiricozzi A, Girolomoni G. The risk of COVID-19 pandemic in patients with moderate to severe plaque psoriasis receiving systemic treatments. Vaccines (Basel). 2020;8:E728. https:\/\/doi.org\/10.3390\/vaccines8040728.","journal-title":"Vaccines (Basel)"},{"key":"1023_CR31","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1080\/14712598.2021.1853698","volume":"21","author":"M Talamonti","year":"2021","unstructured":"Talamonti M, Galluzzo M, Chiricozzi A, Quaglino P, Fabbrocini G, Gisondi P, et\u00a0al. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study. Expert Opin Biol Ther. 2021;21:271\u20137. https:\/\/doi.org\/10.1080\/14712598.2021.1853698.","journal-title":"Expert Opin Biol Ther"},{"key":"1023_CR32","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jaci.2020.10.032","volume":"147","author":"P Gisondi","year":"2021","unstructured":"Gisondi P, Piaserico S, Naldi L, Dapavo P, Conti A, Malagoli P, et\u00a0al. Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: a Northern Italy experience. J Allergy Clin Immunol. 2021;147:558-560.e1. https:\/\/doi.org\/10.1016\/j.jaci.2020.10.032.","journal-title":"J Allergy Clin Immunol"},{"key":"1023_CR33","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/pubmed\/fdaa106","volume":"42","author":"A B\u00e4uerle","year":"2020","unstructured":"B\u00e4uerle A, Teufel M, Musche V, Weism\u00fcller B, Kohler H, Hetkamp M, et\u00a0al. Increased generalized anxiety, depression and distress during the COVID-19 pandemic: a cross-sectional study in Germany. J Public Health (Oxf). 2020;42:672\u20138. https:\/\/doi.org\/10.1093\/pubmed\/fdaa106.","journal-title":"J Public Health (Oxf)"},{"key":"1023_CR34","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1111\/jdv.12999","volume":"29","author":"K Breuer","year":"2015","unstructured":"Breuer K, G\u00f6ldner FM, J\u00e4ger B, Werfel T, Schmid-Ott G. Chronic stress experience and burnout syndrome have appreciable influence on health-related quality of life in patients with psoriasis. J Eur Acad Dermatol Venereol. 2015;29:1898\u2013904. https:\/\/doi.org\/10.1111\/jdv.12999.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1023_CR35","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1046\/j.1365-2133.2002.04899.x","volume":"147","author":"D Vardy","year":"2002","unstructured":"Vardy D, Besser A, Amir M, Gesthalter B, Biton A, Buskila D. Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients. Br J Dermatol. 2002;147:736\u201342. https:\/\/doi.org\/10.1046\/j.1365-2133.2002.04899.x.","journal-title":"Br J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01023-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-023-01023-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01023-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T10:10:13Z","timestamp":1698487813000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-023-01023-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1023"],"URL":"https:\/\/doi.org\/10.1007\/s13555-023-01023-w","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"subject":[],"published":{"date-parts":[[2023,9,14]]},"assertion":[{"value":"17 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.K., S.P., E.J.O., M.E. and B.F. are employed by the Temedica GmbH. M.O. does not have any conflicts of interests to declare. M.A. has served as a consultant, lecturer, researcher, and\/or has received research grants from companies manufacturing drugs for chronic skin diseases, including AbbVie, ALK-Abell\u00f3, Almirall, Amgen, AOK Bundesverband, AOK BW, Bayer, Beiersdorf, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, BSN, Celgene, Centocor, DAK Gesundheit, Dermira, Desitin, Eli Lilly, Flen,Galderma, Genzyme, GlaxoSmithKline, Hexal, Incyte, Janssen, LEO Pharma, Medac, Menlo, Moelnlycke, MSD, Mylan, Novartis, Pfizer, Regeneron, Sandoz, Sanofi, Stallergenes, Trevi, and Urgo und XenoPort. S.G. has no conflict of interest. S. Schneeweis (ORCID# 0000-0003-2575-467X) is participating in investigator-initiated grants to the Brigham and Women\u2019s Hospital from Boehringer Ingelheim and UCB unrelated to the topic of this study. He is a consultant to Aetion Inc., a software manufacturer of which he owns equity. His interests were declared, reviewed, and approved by the Brigham and Women\u2019s Hospital in accordance with their institutional compliance policies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethical approval was not needed for our analysis since the data analysed here retrospectively is anonymized prescription sales data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}